- Curis Inc CRIS stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).
- Four objective responses were recorded with signs of hematologic recovery.
- The data published from 15 patients showed bone marrow blast reductions in all tested doses - 200 milligrams, 300 milligrams, and 400 milligrams twice daily.
- But today, in its Q1 earnings release, the company updated that the 500mg twice daily dosing regimen in the AML/MDS study has exceeded the maximum tolerated dose according to protocol guidelines.
- Two patients in the cohort were observed to have dose-limiting toxicities, one of whom had severe rhabdomyolysis (breakdown of muscle tissue), and the other experienced severe syncope (fainting or passing ou caused by a temporary drop in the amount of blood that flows to the brain).
- Both the adverse events resolved after discontinuation of dosing, said the company.
- Also, the company reported non-clinical data to be presented in a poster at EHA demonstrating synergistic antitumor activity of CA-4948 in combination with azacitidine and venetoclax in leukemia cells.
- Earnings Update: Curis reported a Q1 EPS loss of $(0.11), which missed the analyst consensus loss estimate of $(0.09) but is narrower than the loss of $(0.280 reported a year ago.
- Sales of $2.19 million also missed the analyst consensus estimate of $2.64 million and were down 19.2% Y/Y.
- Cash and equivalents totaled $168.4 million, which is expected to fund its planned operations into 2024.
- Price Action: CRIS shares dropped 14.9% at $13.85 during the premarket session on the last check Thursday.
CRISCuris Inc
$1.19-7.72%
Edge Rankings
Momentum
1.82
Growth
-
Quality
-
Value
41.30
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
